ES2000743A6 - Estuche y procedimiento para preparar una unidad de dosificacion de activador de plasminogeno de tejidos humanos. - Google Patents

Estuche y procedimiento para preparar una unidad de dosificacion de activador de plasminogeno de tejidos humanos.

Info

Publication number
ES2000743A6
ES2000743A6 ES8600558A ES8600558A ES2000743A6 ES 2000743 A6 ES2000743 A6 ES 2000743A6 ES 8600558 A ES8600558 A ES 8600558A ES 8600558 A ES8600558 A ES 8600558A ES 2000743 A6 ES2000743 A6 ES 2000743A6
Authority
ES
Spain
Prior art keywords
dosage unit
pharmaceutical dosage
tpa
plasminogen activator
human tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8600558A
Other languages
English (en)
Inventor
Thomas Robert Melefyt
Chester Allen Meyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of ES2000743A6 publication Critical patent/ES2000743A6/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Abstract

EL ESTUCHE DESCRITO COMPRENDE UNO O MAS RECIPIENTES ESTERILES DE TPA (ACTIVADOR DE PLASMINOGENO DE TEJIDOS HUMANOS) EN FORMA LIOFILIZADA Y UNO O MAS RECIPIENTES ESTERILES DISTINTOS DE SOLUCION PARA RECONSTITUCION, HABIENDO UN TAMPON EN UNO O AMBOS RECIPIENTES Y SELECCIONANDOSE EL TAMPON, LA SOLUCION PARA RECONSTITUCION Y LAS CANTIDADES DE TPA Y DE SOLUCION DE MANERA QUE PROPORCIONEN UNA UNIDAD DE DOSIFICACION FARMACEUTICA QUE COMPRENDE 0,1-15 MG/ML DE TPA A PH 3,5-5,5. POR SU PARTE, EL PROCEDIMIENTO COMPRENDE DISOLVER TPA EN UN DISOLVENTE ACUOSO AL PH CITADO HASTA ALCANZAR LA CONCENTRACION DEL TPA MENCIONADA. LA UNIDAD DE DOSIFICACION OBTENIDA ES UTIL PARA ADMINISTRACION PARENTERAL, PARTICULARMENTE EN TERAPIA TROMBOLITICA.-
ES8600558A 1985-07-29 1986-07-24 Estuche y procedimiento para preparar una unidad de dosificacion de activador de plasminogeno de tejidos humanos. Expired ES2000743A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75978585A 1985-07-29 1985-07-29

Publications (1)

Publication Number Publication Date
ES2000743A6 true ES2000743A6 (es) 1988-03-16

Family

ID=25056946

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8600558A Expired ES2000743A6 (es) 1985-07-29 1986-07-24 Estuche y procedimiento para preparar una unidad de dosificacion de activador de plasminogeno de tejidos humanos.

Country Status (15)

Country Link
EP (1) EP0211592A3 (es)
JP (1) JPS6236332A (es)
KR (1) KR870000918A (es)
CN (1) CN86105526A (es)
AU (1) AU593566B2 (es)
DK (1) DK352686A (es)
ES (1) ES2000743A6 (es)
FI (1) FI863077A (es)
GR (1) GR861961B (es)
HU (1) HU198264B (es)
NO (1) NO863029L (es)
PH (1) PH22989A (es)
PT (1) PT83075B (es)
ZA (1) ZA865652B (es)
ZW (1) ZW14486A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
BE904831A (fr) * 1985-05-28 1986-11-27 Wellcome Found Composition d'activateur tissulaire du plasminogene.
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
DE3845000C2 (de) * 1987-07-10 1998-11-19 Novartis Ag Anwendung von Octreotid zur Behandlung von Brustkrebs
US4929560A (en) * 1988-02-03 1990-05-29 Damon Biotech, Inc. Recovery of tissue plasminogen activator
DE3806562A1 (de) * 1988-03-01 1989-09-14 Alpha Therapeutic Gmbh Zweikammerspritze mit einer fuellung aus aktivitaetsempfindlichem humanen protein als wirkstoff
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
GB8814604D0 (en) * 1988-06-20 1988-07-27 Wellcome Found Medicaments
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
AU6470590A (en) 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
US5366730A (en) * 1989-12-20 1994-11-22 Boehringer Mannheim Gmbh Stabilized compositions having human tissue type plasminogen activator enzymatic activity
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro
ATE132373T1 (de) * 1991-04-16 1996-01-15 Boehringer Mannheim Gmbh Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
US5272076A (en) * 1991-06-13 1993-12-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders using an adduct of t-PA
US5747447A (en) * 1992-04-30 1998-05-05 Cor Therapeutics Stable polypeptide composition
DE10199044I2 (de) * 1992-06-03 2006-02-09 Genentech Inc Varianten des Gewebeplasminogenaktivators mit verbesserter Therapeutischer wirkung
US7879341B2 (en) 2004-07-26 2011-02-01 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
KR102194891B1 (ko) 2020-07-08 2020-12-28 대상 주식회사 계란프라이 조리장치

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8003402A (nl) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
BE904831A (fr) * 1985-05-28 1986-11-27 Wellcome Found Composition d'activateur tissulaire du plasminogene.
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法

Also Published As

Publication number Publication date
NO863029L (no) 1987-01-30
AU6064786A (en) 1987-02-05
DK352686D0 (da) 1986-07-24
ZW14486A1 (en) 1986-10-22
FI863077A0 (fi) 1986-07-28
GR861961B (en) 1986-11-26
PT83075B (en) 1988-07-13
EP0211592A2 (en) 1987-02-25
PT83075A (en) 1986-08-01
ZA865652B (en) 1987-11-25
EP0211592A3 (en) 1988-03-02
AU593566B2 (en) 1990-02-15
CN86105526A (zh) 1987-02-04
JPS6236332A (ja) 1987-02-17
FI863077A (fi) 1987-01-30
HUT42953A (en) 1987-09-28
DK352686A (da) 1987-01-30
PH22989A (en) 1989-02-24
NO863029D0 (no) 1986-07-28
HU198264B (en) 1989-09-28
KR870000918A (ko) 1987-03-10

Similar Documents

Publication Publication Date Title
ES2000743A6 (es) Estuche y procedimiento para preparar una unidad de dosificacion de activador de plasminogeno de tejidos humanos.
HK15293A (en) Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
HK1003980A1 (en) Dosage form for dispensing drug and human therapy
AU567236B2 (en) Pharmaceutical formulation of tissue plasminogen activator
NO862095L (no) Farmasoeytiske preparater inneholdende vevsplasmnogenaktivitator og fremgangsmaate for deres fremstilling.
HU907959D0 (en) Medical preparations
ES8608490A1 (es) Procedimiento de obtencion de una preparacion farmaceutica en forma de liberacion lenta y que comprende pinacidil (n'-ciano-n-4-piridil-n'-1, 2, 2-trimetil-propilguanidina), opcionalmente junto con otros componentes
NZ217331A (en) Tissue plasminogen activator derivatives and genetically engineered product
IL91774A0 (en) Preparation of plasminogen activator expressed in prokaryotes
HUT63441A (en) Megakariocyte colony stimultating factor protein
NO168055C (no) Fremgangsmaate for fremstilling av human vevplasminogenaktivator og urokinase-type plasminogenaktivator.
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
IL78450A0 (en) Agent containing tissue plasminogen activator(t-pa)
IL79521A0 (en) Pharmaceutical dosage unit of tissue plasminogen activator
EP0225177A3 (en) Dna sequence coding for human tissue plasminogen activator
IL86887A0 (en) Improved human tissue plasminogen activator and its use
ZA862976B (en) Human tissue plasminogen activator mutants
IE872091L (en) Combination of tissue plasminogen activator and a¹prostaglandin
PL332035A1 (en) Transdermal therapeutic system including an estriol-containing composition of active substances
GB8815245D0 (en) New tissue plasminogen activator
SU1807595A1 (ru) Средство для лечения отравлений ртутью
IE882534L (en) Peg complex of tissue plasminogen activator
AP8500009A0 (en) New phenoxypropanolamine salts and pharmaceutical preparations thereof.
ZA872694B (en) Tissue plasminogen activator(tpa)derivative and its preparation
AU609337B2 (en) Tissue plasminogen activator (t-pa) muteins and processes for the preparation thereof

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20000503